PT - JOURNAL ARTICLE AU - Paul S. Fitzmaurice AU - Junchao Tong AU - Mehrdad Yazdanpanah AU - Peter P. Liu AU - Kathryn S. Kalasinsky AU - Stephen J. Kish TI - Levels of 4-Hydroxynonenal and Malondialdehyde Are Increased in Brain of Human Chronic Users of Methamphetamine AID - 10.1124/jpet.106.109173 DP - 2006 Nov 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 703--709 VI - 319 IP - 2 4099 - http://jpet.aspetjournals.org/content/319/2/703.short 4100 - http://jpet.aspetjournals.org/content/319/2/703.full SO - J Pharmacol Exp Ther2006 Nov 01; 319 AB - Animal studies suggest that the widely used psychostimulant drug methamphetamine (MA) can harm brain dopamine neurones, possibly by causing oxidative damage. However, evidence of oxidative damage in brain of human MA users is lacking. We tested the hypothesis that levels of two “gold standard” products generated from lipid peroxidation, 4-hydroxynonenal (one of the most reactive lipid peroxidation aldehyde products) and malondialdehyde, would be elevated in post mortem brain of 16 dopamine-deficient chronic MA users compared with those in 21 matched control subjects. Derivatized aldehyde concentrations were determined by gas chromatography-mass spectrometry. In the MA group, we found significantly increased levels of 4-hydroxynonenal and malondialdehyde in the dopamine-rich caudate nucleus (by 67 and 75%, respectively) and to a lesser extent in frontal cortex (48 and 36%, respectively) but not in the cerebellar cortex. Approximately half of the MA users had levels of 4-hydroxynonenal falling above the upper limit of the control range in caudate and frontal cortex. A subgroup of MA users with high brain drug levels had higher concentrations of the aldehydes. Our data suggest that MA exposure in human causes, as in experimental animals, above-normal formation of potentially toxic lipid peroxidation products in brain. This provides evidence for involvement of oxygen-based free radicals in the action of MA in both dopamine-rich (caudate) and -poor (cerebral cortex) areas of human brain. The American Society for Pharmacology and Experimental Therapeutics